Gossamer Bio
Yahoo Finance • 3 days ago
Gossamer Bio announces $250m in funding to advance seralutinib
Gossamer Bio has announced a private placement agreement valued at up to $250m, including $150m of committed capital intended to support the development and potential US Food and Drug Administration (FDA) approval of seralutinib. Seraluti... Full story
Yahoo Finance • 5 days ago
Sector Update: Healthcare Stocks Advance in Afternoon Trading
Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 30 days ago
Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired
(RTTNews) - Today's top biotech gainers include Entera Bio, following an oversubscribed private placement financing; Gossamer, which is progressing toward a planned Seralutinib NDA submission in September; First Tracks, which has been firi... Full story
Yahoo Finance • last month
Gossamer Sets September NDA Filing For Seralutinib In Pulmonary Arterial Hypertension; Stock Up
(RTTNews) - Gossamer Bio, Inc. (GOSS) announced that following a productive Pre-NDA Type B meeting with the U.S. FDA and receipt of the official meeting minutes, the company is moving forward with a planned NDA submission for Seralutinib i... Full story
Yahoo Finance • 3 months ago
DEADLINE ALERT for GOSS, NUAI, and MEDP: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
LOS ANGELES, June 01, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story
Yahoo Finance • 3 months ago
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, May 31, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS) for vio... Full story
Yahoo Finance • 3 months ago
GOSS FINAL DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS
SAN FRANCISCO, May 31, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer secu... Full story
Yahoo Finance • 3 months ago
GOSS DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action – GOSS
NEW YORK, May 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the “Class... Full story
Yahoo Finance • 3 months ago
GOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. (NASDAQ:GOSS) Investors with Large Losses to Contact the Firm Before Monday June 1st
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Gossamer (GOSS) To Contact Him Directly To Discuss Their Options If you purchased or acquired Gossamer securities between June 16, 2... Full story
Yahoo Finance • 3 months ago
GOSSAMER DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the “Class... Full story
Yahoo Finance • 3 months ago
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSS
SAN FRANCISCO, May 27, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer secu... Full story
Yahoo Finance • 3 months ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyto... Full story
Yahoo Finance • 3 months ago
DEADLINE APPROACHING: Berger Montague Advises Gossamer Bio, Inc. (NASDAQ: GOSS) Investors to Inquire About a Securities Fraud Class Action by June 1, 2026
PHILADELPHIA, May 26, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) (“Gossamer” or the “Company”) on behalf of investors who purchased... Full story
Yahoo Finance • 3 months ago
GOSS 10-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS
SAN FRANCISCO, May 22, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer secu... Full story
Yahoo Finance • 3 months ago
הודעת מועד אחרון לתביעה ייצוגית נגד GOSSAMER: רוזן, יועץ למשקיעים מוביל, מעודד משקיעים ב- Gossamer Bio, Inc. עם הפסדים של יותר מ-100 אלף דולר לקבל ייעוץ משפטי לפני המועד האחרון החשוב בתביעה ייצוגית לניירות ערך – GOSS
ניו יורק, May 22, 2026 (GLOBE NEWSWIRE) -- מדוע: משרד רוזן עורכי דין (Rosen Law Firm), משרד עורכי דין בינלאומי העוסק בזכויות משקיעים, מזכיר לרוכשים את ניירות הערך של Gossamer Bio, Inc. (נאסד"ק: GOSS) בין התאריכים 16ביוני2025 עד 20בפברו... Full story
Yahoo Finance • 3 months ago
GOSSAMER DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the “Class... Full story
Yahoo Finance • 3 months ago
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and certain o... Full story
Yahoo Finance • 3 months ago
DEADLINE ALERT for PINS, NUAI, GOSS, MEDP: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
BENSALEM, Pa. , May 19, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story
Yahoo Finance • 3 months ago
Gossamer Bio Q1 Net Loss Expands; Eyes On The Pre-NDA Meeting With FDA For Seralutinib W In Mid-June
(RTTNews) - Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company, on Monday announced its financial results for the first quarter ended March 31, 2026, reflecting a wider net loss and provided a near-term milestone update... Full story
Yahoo Finance • 3 months ago
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the “Class... Full story